Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling.

@article{Khan2010TrimetazidineAA,
  title={Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling.},
  author={Mahmood Khan and Sarath Meduru and Mahmoud Mostafa and Saniya Aslam Khan and K{\'a}lm{\'a}n Hideg and Periannan Kuppusamy},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2010},
  volume={333 2},
  pages={421-9}
}
Trimetazidine [1-(2,3,4-trimethoxybenzyl)piperazine; TMZ] is an anti-ischemic cardiac drug; however, its efficacy and mechanism of cardioprotection upon reperfusion are largely unknown. The objective of this study was to determine whether TMZ, given before reperfusion, could attenuate myocardial reperfusion injury. Ischemia/reperfusion (I/R) was induced in rat hearts by ligating the left anterior descending (LAD) coronary artery for 30 min followed by 48 h of reperfusion. TMZ (5 mg/kg b.wt… CONTINUE READING